| Names | |
|---|---|
| Preferred IUPAC name | rac-9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid |
| Other names | Oflox Oflin Oflomac Oflotas Oflo Ofloxin |
| Pronunciation | /əˈflɒksəˌsɪn ˈtæb.lɪt/ |
| Identifiers | |
| CAS Number | 82419-36-1 |
| Beilstein Reference | Beilstein Reference 62684 |
| ChEBI | CHEBI:7735 |
| ChEMBL | CHEMBL1439 |
| ChemSpider | VYSWONIAMFBLJZ-UHFFFAOYSA-N |
| DrugBank | DB01165 |
| ECHA InfoCard | echa infoCard: 100.038.370 |
| EC Number | 6191850 |
| Gmelin Reference | Gmelin Reference 83346 |
| KEGG | D08385 |
| MeSH | D009888 |
| PubChem CID | 4583 |
| RTECS number | RG5840000 |
| UNII | 02F90AE084 |
| UN number | UN3248 |
| CompTox Dashboard (EPA) | Ofloxacin Tablet CompTox Dashboard (EPA) string: **DTXSID7032625** |
| Properties | |
| Chemical formula | C18H20FN3O4 |
| Molar mass | 361.370 g/mol |
| Appearance | White to pale yellow, round, film-coated tablet |
| Odor | Odorless |
| Density | 0.6 g/cm³ |
| Solubility in water | Sparingly soluble in water |
| log P | -0.39 |
| Acidity (pKa) | 6.1 |
| Basicity (pKb) | ~6.05 |
| Dipole moment | 0.00 D |
| Pharmacology | |
| ATC code | J01MA01 |
| Hazards | |
| Main hazards | May cause serious allergic reactions, tendon rupture, nerve damage, and central nervous system effects. |
| Pictograms | ["pregnancy_warning", "breastfeeding_warning", "alcohol_interaction", "kidney_warning", "liver_warning", "drowsiness_warning", "machinery_warning"] |
| Signal word | Warning |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Use only as directed by a physician. Store in a cool, dry place away from light. |
| LD50 (median dose) | LD50 (median dose) of Ofloxacin Tablet: "5450 mg/kg (oral, rat) |
| NIOSH | 68115-5047 |
| REL (Recommended) | 200 mg |
| IDLH (Immediate danger) | Not Established |
| Related compounds | |
| Related compounds | Levofloxacin Ciprofloxacin Moxifloxacin Norfloxacin Gemifloxacin Sparfloxacin Gatifloxacin Enoxacin Lomefloxacin Pefloxacin |
| Category | Description |
|---|---|
| Product Name | Ofloxacin Tablet |
| IUPAC Name | 9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (Ofloxacin as active pharmaceutical ingredient in finished oral solid dosage form) |
| Chemical Formula | C18H20FN3O4 (for ofloxacin API; the tablet contains excipients based on formulation requirement) |
| Synonyms & Trade Names | Ofloxacin Oral Tablet, Oflox, Oflodal, Floxin (trade names vary by region and marketing authorization) |
| HS Code & Customs Classification | HS Code: 3004.50 (Medicaments containing antibiotics, put up in measured doses for retail sale. Exact digits may differ depending on region and local customs authority classification for reference API, finished formulation, or packaging form.) |
In our industrial production of ofloxacin tablets, quality begins at characterization of incoming ofloxacin active ingredient. The API is sourced from manufacturing lines with controlled synthesis routes—processes based on fluorination and heterocycle formation, which typically introduce specific impurities during side-chain synthesis and ring closure. Each incoming lot is tested for identity and chemical profile consistent with pharmacopeial standards. Excipients used in tablet formulation depend on target dissolution, stability, compressibility, and customer specification. The chosen blend directly impacts tablet robustness and shelf life in distribution.
RQ-PCR and HPLC methods under GMP dictate both the content uniformity and limit-setting for impurity profiles. Most impurity controls focus on synthesis byproducts, residual solvents, and degradation behavior in final dosage form, rather than in the ofloxacin molecule alone. For customers requiring pediatric or low-dose variants, the excipient matrix and tablet diameter shift to meet regulatory dissolution and mass uniformity.
Ofloxacin’s performance in tablet form depends on crystal habit (shape and particle size), which directly affects blending with excipients and downstream compressibility. Particle size control and flowability determine hopper consistency and automatable blend uniformity. Purification typically uses crystallization and recrystallization techniques for API prior to formulation, with solid-state form confirmed by XRPD or FTIR. Control of polymorphic form is essential—hydration states and particle surface area influence both product stability and rate of drug release in the gastric environment.
Release testing combines dissolution, disintegration, and assay results, benchmarked against both local pharmacopoeias and international guidelines. Batch-to-batch consistency depends on precise granulation, press control, and in-process visual and analytical checkpoints. Finished tablets undergo packaging under controlled humidity and temperature to prevent degradation—especially relevant for international shipments in variable climates. In our experience, real-world deviations often arise from excipient lot variability, environmental shifts in production suites, or process drift in API milling step; each source is controlled through targeted in-process checks and documented deviation management.
HS Code assignment responds to regional customs practices. In some jurisdictions, regulators demand further sub-classification to distinguish between API, bulk packed tablets, or finished retail packs. This requires careful documentation at export to avoid holdups and regulatory audit.
Ofloxacin tablets are compressed solid dosage forms, typically white to pale yellow in color. The shade and finish sometimes shift based on excipient content or tablet coating. No distinct odor is present under standard packaging, but fine powder from crushed tablets may have a faint chemical scent. In industrial production, tablet hardness and friability targets reflect the demands of downstream film-coating or packaging operations.
Precise melting and boiling points apply to the pure API, not the finished tablet. Ofloxacin as an API presents a defined melting point, but excipients, moisture content, and compression forces in tablet form typically obscure sharp transitions. Flash point and volatility do not hold process relevance at the finished dosage level.
Bulk density and tapped density measurements are critical for granulation and direct compression blending. Target values are grade- and batch-dependent, tailored according to granulation method, blend flowability, and press speed. Variation outside tolerance complicates uniform dosing and coating.
Chemical stability depends on excipient compatibility and packaging. Ofloxacin’s carboxylic acid group shows moderate sensitivity to moisture; alkaline fillers may increase risk of degradation. Reducing agents or exposure to light can induce color change or API breakdown in susceptible grades.
Ofloxacin API is moderately soluble in water and sparingly soluble in some organic solvents. Solubility shifts with pH, which is exploited in formulation development to optimize bioavailability. Tablet disintegration and dissolution rates are monitored batch-to-batch for compliance. For analytical work, buffers or dilute acid/base improve sample preparation and extraction efficiency.
Industrial manufacturing supports multiple grades, subject to targeted impurity limits and content uniformity. Finished tablets must meet identity, assay, and dissolution targets specified by pharmacopeia or customer requirements. Each batch’s specifications are documented in quality agreements and tested per registered method.
| Parameter | Reference Grade | Release Limits | Notes |
|---|---|---|---|
| Assay (API) | Pharmacopeia | Grade-specific | Based on labeled strength |
| Impurity Content | Pharmacopeia/Custom | Customer/Region-Specific | Controlled by synthesis & purification |
| Disintegration | Pharmacopeia | Defined by dosage form | Influenced by excipient choice |
| Dissolution | Pharmacopeia/Custom | Q value, site-specific | May differ by market |
| Microbial Limit | Pharmacopeia | Grade-dependent | Critical for non-sterile products |
Major impurities derive from synthetic route, intermediate stability, and API handling. Residual solvents, unreacted starting materials, and process by-products fluctuate based on solvent recovery and purification sequence. Quality-controlled batches show impurity limits set by pharmacopeia or negotiated customer specs; out-of-specification batches are subject to investigation and rework.
Analytical release relies on compendial HPLC, UV spectroscopy, loss on drying, and microbial assays. Validation must prove method specificity against known degradation products and excipient peaks per ICH and regulatory standards. In-process checks ensure blend uniformity and tablet weight consistency before final approval.
Selection targets pharmaceutical grade API and compendial excipients only. Critical input variables include particle size, moisture content, and compatibility; suppliers are audited for consistency, regulatory compliance, and traceability. Sourcing logic weighs price, lead time, and impurity risk.
API synthesis follows a multi-step process involving quinolone core construction, halogenation, and ring closure. Choice of synthesis route responds to regional regulatory requirements, availability of protected intermediates, and desired impurity minimization. The reaction sequence uses established organic transformations; post-reaction workup and intermediate purification play a key role in cost control and impurity management.
Key control points concentrate on critical blend attributes (particle size, flow properties, binder content), granulation moisture, and compression force. Impurity removal in the API stage relies on recrystallization, solvent washes, and sometimes column chromatography. Process validation covers blending, sifting, and final tablet compression, demanding batch records and real-time monitoring.
Each lot must pass visual inspection, blend uniformity, and microbial limits. QA team controls sampling at defined intervals, applies validated test methods, and maintains documentation for traceability. Released products demonstrate compliance with pharmacopeial assay, dissolution, and impurity limits as per commitment to customers or regulators.
Ofloxacin’s core structure tolerates controlled hydrolysis, reduction, and minor alkylation under prescribed laboratory conditions, useful for producing related substances as analytical standards. Industrially, the risk of unplanned reaction increases in the presence of strong acid or base, justifying pH and water control in storage and handling.
Critical reactions in synthesis require anhydrous solvents, controlled temperature profiles, and typically a protected atmosphere to avoid hydrolysis or oxidation. Catalytic processes are applied selectively, often depending on raw material cost or product purity targets.
Downstream chemical modification rarely occurs at the final dosage stage. Synthesis intermediates yield potential for ofloxacin derivatives development, subject to patent or regulatory constraints. Some derivatives serve as research standards or internal markers in analytical method validation.
Tablets store best at controlled room temperature, moderate humidity, and minimal light exposure to reduce risk of discoloration or hydrolysis. Sealed containers use desiccants for humidity-sensitive grades. Direct exposure to strong lights, bulk oxygen, or extreme temperatures increases breakdown risk, particularly in bulk packaging prior to blistering.
Blister packs and HDPE bottles provide acceptable protection if selected for API-excipient compatibility and migration risk. Selection factors consider permeability, interaction with tablet coatings, and leachables challenge.
Actual shelf life depends on packaging, excipient system, and storage environment. Typical degradation appears as color change, odor development, or drop in assay value. Shelf life for a given batch is assigned following stability studies adhering to ICH guidelines.
Standard industrial GHS labeling applies to Ofloxacin as an API powder, not to the finished tablet. Manufacturer labeling reflects API-specific hazards, which include possible irritant classification dependent on dustiness and exposure.
API handling may call for hazard statements regarding respiratory sensitization and skin/eye contact risk. Processing areas use localized ventilation and gloves for dust-phase handling.
Toxicological endpoints, including acute oral and dermal effects, are referenced in regulatory dossiers and confirmed by batch-level impurity control. Chronic exposure at low levels is avoided through segregation, personal protection, and environmental controls in the manufacturing zone.
Workplace exposure limits for API dust conform to regional regulatory standards. Tablets in finished form present low exposure risk during standard handling and packaging. Training enforces good industrial hygiene, spill cleanup protocols, and appropriate waste management for scrap or returned material.
Ofloxacin tablet production hinges on stringent in-house synthesis of the active pharmaceutical ingredient, controlled wet granulation, and tableting lines with validated batch release protocols. Output capacity fluctuates with scheduled API campaigns, GMP line allocation, and turnaround cycles for cleaning verification. Typical lines alternate between batch campaign runs for different market grades: domestic, export, and hospital tenders. Production lead times adjust to both the sales forecast, real-time procurement cycles of key raw materials, and required regulatory batch-release testing, with longer durations allocated for protocol validation batches destined for regulated markets.
Lead time aligns with ongoing batch status, customer registration documentation, and analytical method bridging. Orders with novel packaging specifications or requiring new-country-release documentation extend typical lead times, with actual minimum order quantities tied to the desired packaging format and presentation (e.g., unit-dose blister vs. hospital bulk). Larger lots shipped under single CoA per batch allow for shorter planning horizons, subject to continuous campaign scheduling.
Primary packaging typically covers alu-alu and PVC/Alu blister, HDPE bottle, and strip pack, with negotiation possible for customer-specific outer cartons, security coding, and leaflet requirements. Cartonization for export runs adapts to destination country labeling, serial requirements, and secondary info-matching.
Shipping routes depend on destination customs clearance, agreed incoterms, and shipment size. Volume export shipments use climate-controlled container forwarders due to sensitivity to temperature excursions. Payment terms reflect length of supply relationship, with export credit most commonly LC-at-sight for new partners, and open account available for established, credit-insured partners.
Ofloxacin’s raw material cost is heavily determined by the input price of fluorinated intermediates, caustic reagents, and access to high-purity solvent recovery. The market remains sensitive to price shocks in the feedstock supply chain, especially for key benzoxazine and piperazine intermediates, which have witnessed volatility due to changing output in major producing regions. Process yield, impurity generation management, and API purification losses add direct manufacturing overhead.
Volume swings in demand from India’s hospital procurement rounds and China’s bulk API tenders often lead to near-term volatility, driving spot purchases of intermediates at above-contracted rates. Environmental regulatory controls on upstream chemical manufacturers, especially related to pollutant discharge and solvent management, frequently cause supply disruption, tightening raw material availability and raising input costs. Transition to renewable or low-emission process options may introduce stepwise increases in cost for manufacturers investing in compliant infrastructure.
API grade and documented purity, especially for ICH-compliant markets, command a premium driven by release criteria, impurity profiling, and full traceability batch records. Excipients and packaging materials certified to pharmacopeial standards for Western markets (US/EU/JP) further elevate costs, primarily due to additional analytical release and batch-specific validation work. Locally registered generics for non-regulated markets may use lower-cost inner packaging, contributing to wider price bands between regulated and non-regulated product shipments. Packaging certification, serialization, and tamper-evidence for finished goods destined for the EU or US are cost-intensive drivers, with traceability and anti-counterfeiting protocols mandating additional upstream investment in batch documentation and serialization systems.
Demand for ofloxacin tablets revolves around antimicrobial usage statistics across Asia Pacific, where syndromic treatment programs and public sector procurement underpin large-volume uptake. Export markets follow a cycle of hospital and government tendering, with variable buying cycles in emerging economies creating order volatility that can feed back into pricing. Regulatory approvals and centralized purchasing in Europe and the US coordinate bulk order planning, while Japan draws stable demand from mature market maintenance use.
Renminbi input pricing in China routinely sets the effective floor pricing for API and finished tablet supply, while India's large-scale manufacturers drive spot and forward contract volumes through a mix of public tender and branded generics channels. US and EU markets demand full regulatory submission-backed product grades, requiring enhanced documentation and finished goods stability assurance. Fluctuations in Japanese procurement are supported by higher certification thresholds but occur in smaller volume waves.
Indications for 2026 build off observable trends in regulatory pressure on upstream API synthesis in China, ongoing cost pass-throughs related to compliance adaptation, and rising labor and energy rates in key production zones. Manufacturers focusing on portfolio-level chemical compliance, digital batch tracking, and close-loop solvent recovery will likely sustain or modestly increase price points in regulated markets. Discounted offers in emerging markets will remain closely linked to local currency fluctuations, tax incentives, and degree of packaging customization requested.
This commentary references internal batch records, customer procurement histories, published tender outcomes in key procurement economies, and real-time feedstock market trends. Peer manufacturer meetings, regulatory database updates, and international shipment transactional data integrate in-house and market intelligence for scenario planning.
Recent quarters saw sharp price moves in fluoroquinolone intermediates following additional environmental regulation rollouts in Eastern China and a fire incident at a key solvent supplier in India. The impact rippled through both API and finished formulation markets, with exporters accelerating scheduled batches ahead of expected raw material rationing.
Ongoing updates to ICH Q3D and local pharmacopoeia heavy metal thresholds prompted internal process reviews and investment in additional in-process analytical verification of metal catalysts and solvents. GMP inspection cycles in both domestic and regulated export facilities triggered modifications to batch documentation and strengthened chain-of-custody procedures for both API and excipient testing. Serialization rules effective in the EU and US led to new investment in coding and anti-counterfeiting technology.
We adjusted intermediate procurement windows and built buffer stock of critical precursors ahead of major regulatory announcements. Production scheduling has shifted to sequence compliant and non-compliant batches independently, reducing cross-contamination risk in multipurpose plants. Formulation adaptation routes for destinations with evolving regulatory landscapes remain under ongoing process development, tying product launch cycles tightly to successful registration or re-registration milestones in each target market.
Ofloxacin tablets occupy a central role in pharmaceutical manufacturing, primarily as oral fluoroquinolone antibiotics prescribed for bacterial infections across outpatient and hospital settings. Most industrial clients process Ofloxacin API into finished dosage forms for the regulated drug market, while a minority apply this material to research, stability trials, or formulation development. Finished dose manufacturers, hospital-supply chains, contract production organizations, and government procurement programs each present distinct requirements for both raw material properties and supply consistency.
| Grade | Common Applications | Key Selection Considerations |
|---|---|---|
| Pharmaceutical Grade | Oral tablet production for human use, prescription packaging, clinical trial batches | Complies with pharmacopeial monographs; maintained traceability; focus on low impurity load; mandatory full analytical validation; aligns with finished dose regulatory needs |
| Research Grade | Analytical method development, pilot formulation, preclinical screening | Available in smaller batch size; may not meet full ICH/USP/EP testing; supplied under R&D status certificate |
| Veterinary Grade | Animal health product formulation, veterinary hospitals | Permits wider impurity profile; alignment with local veterinary pharmacopeial standards; not for human drug market |
| Parameter | Oral Human Drug Use | R&D/Analytical | Veterinary Use |
|---|---|---|---|
| Assay (API Content) | Typically conforms to USP/EP/IP pharmacopeia standards, batch certificates released per order specifications | Less stringent; determined per lot, values may vary based on research demand | Defined by animal pharmacopeia or customer specification, may accept lower assay thresholds |
| Impurity Profile | Consistently meets regulated thresholds; monitoring and exclusion of pharmacologically active or genotoxic byproducts; subject to regulatory filing documentation | Controlled but not always fully documented; supports method validation and exploratory studies | Broader tolerance; managed for non-human use prioritizing economic feasibility |
| Microbial Limits/Bioburden | Extensively managed during both synthesis and packaging; periodic sterility monitoring; validated cleaning protocols for processing equipment | Basic monitoring only; not always tested per batch | Generally required only at points dictated by animal health standards |
| Particle Size Distribution | Specifications established for downstream blend uniformity and tablet compressibility; measured using laser diffraction or sieve analytics as per client’s process route | Evaluated as relevant for formulation screening | May remain undefined unless required for certain veterinary dosage forms |
| Residual Solvents | Consistently quantified per ICH Q3C limits; documented at batch release | Monitoring performed pragmatically | Checked according to regional animal health regulations |
Start by establishing the target use: human pharmaceutical manufacture, veterinary product, or analytical research. The intended application determines all baseline compliance, purity, and documentation requirements, including whether pharmacopeial monograph or a company-specific protocol takes priority.
Review the local and international regulations that the final product must follow. Regulatory binding commits the manufacturer to producing under GMP, providing certificates of analysis that match pharmacopeial standards, and supporting full batch traceability. For research and veterinary uses, requirements sometimes differ and should be clarified upfront.
Pharmaceutical production demands tight control of impurity levels, with extensive batch monitoring, genotoxic impurity testing, and analytical method validation. R&D or veterinary applications occasionally tolerate broader impurity profiles. Purity is adjusted by choosing the process route, refining purification protocols, and segregating production for different end-markets. Final commercial use should guide the acceptable profile for assay, impurities, residual solvents, and bioburden.
Production batch scale and purchase quantity may affect access to certain grades or batch segmentation. High-volume or long-term contracts generally secure priority allocation from GMP lots and enable custom release criteria. Lower volumes, especially for early-stage R&D, typically pull from pilot or lab-scale batches, potentially at a premium.
Production teams recommend requesting a sample lot to conduct internal compatibility, blending, and analytical verification before large-scale commitment. The technical team coordinates sample preparation, supplies supporting documentation, and gathers feedback for final grade adjustment. This step allows both sides to confirm the match between grade properties and downstream process needs.
Raw material quality, route selection, process control, and batch reviews shape the final Ofloxacin grade outcome. Choosing the starting material (racemic or enantiopure), designing the synthesis path for impurity minimization, and implementing robust purification ensure predictable product parameters. Impurity control involves both in-process testing and targeted removal steps, particularly to address regulated impurities under ICH guidance.
During each batch’s production, in-process controls catch deviations early. Sampling at critical points—such as post-synthesis, pre-crystallization, and finished API isolation—feeds back into the continuous improvement loop. Each lot receives a full impurity, residual solvent, and assay panel according to the matched grade specification. Batch consistency is promoted by centralized recipe management, environmental conditioned storage, and positive sample traceability post-packaging.
Release standards tie to both customer application demand and internal process target windows. Certificates of analysis reference either global pharmacopeia, customer-approved specifications, or, for research, a tech sheet outlining analytical results and reference standards.
As the manufacturing unit directly producing Ofloxacin Tablets, we maintain comprehensive quality management systems supported by internationally recognized certifications. Our facilities implement Good Manufacturing Practice (GMP) standards validated by regular internal and third-party audits. The site upholds ISO 9001-based quality control, which governs all procedures for batch consistency, cross-contamination prevention, material traceability, and operator qualification.
Actual compliance depends on ongoing regulatory expectations, market region, and the finished product’s specification. Production lines dedicated to pharmaceuticals undergo more rigorous environmental monitoring and record-keeping than bulk API-only facilities, leading to variability in the control environment by grade.
For Ofloxacin Tablets intended for human therapeutic use, our site accommodates both region-specific dossiers and broader international regulatory requirements. We ensure all supplied product meets pharmacopoeial specifications relevant to the destination—such as the USP, EP, or JP monograph—subject to the final client’s market and regulatory filing plan. Product grades vary for regulated (branded and generic medicine manufacturing) and unregulated markets, influencing not only test standards but also the scope of stability studies, impurity profiling, and traceability documentation.
Each commercial batch is accompanied by a Certificate of Analysis with values reported according to release criteria established in the registration file and the technical agreement with the customer. Where required, supplementary documents such as Drug Master Files (DMF), GMP certificates, and others are available after authorization.
From sourcing raw materials to final tablet release, our documentation system tracks critical stages including incoming quality checks, in-process controls, and end-product analytics. Batch Manufacturing Records and Analytical Reports are retained for traceability periods in line with GMP protocols and can be made accessible for authorized customer audits.
Release documentation reflects detailed quality assessments—analytical method validation, equipment calibration records, and impurity profile characterization. Certificates and batch documentation are finalized by our Qualified Person following thorough review. Additional technical reports, such as stability data or process validation summaries, can be supplied upon request, as dictated by the requirements of major regulatory agencies.
Production planning for Ofloxacin Tablets is organized around forecast-based and contract-based commitments. Dedicated tableting lines and validated packaging resources enable stable, long-term supply to both high-volume pharmaceutical clients and smaller-scale buyers with fluctuating demand. In practice, we prioritize allocation for partners with forecast agreements, but contract flexibility is available for project-based or pilot-scale orders by mutual arrangement.
Business cooperation plans adapt to varying procurement cycles—institutional tenders, brand launches, or regular reorder models—through tailored volume allocation, flexible lead times, and batch reservation options. Manufacturing capacity and raw material safety stock build-up can be structured to minimize interruptions in case of unplanned market changes or supply chain pressures.
Our core production capacity for Ofloxacin Tablets is structured around modular, validated production suites that can be adjusted to new campaign volumes as needed. This modularity supports both sustained high-throughput campaigns and controlled pilot productions. Batch release schedules and logistics planning coordinate closely with client inventory cycles to mitigate out-of-stock risk.
Production scale is routinely reviewed in light of raw material sourcing reliability, warehouse turnover, and downstream logistics lead times. Should upstream supply chain volatility arise (such as intermediate API constraints), priority is given to ongoing framework agreement holders while keeping communication transparent regarding expected timelines and alternatives.
Samples for Ofloxacin Tablets are prepared according to internal reference quality and in compliance with client-indicated specifications. Requests for samples undergo review to clarify intended end-use, regulatory filing requirements, and preferred analytical parameters. After approval, retained reference-standard batches are shipped under registered cold-chain or ambient conditions, matched to the sample’s stability profile.
Sample volumes are adjusted depending on analytical, pre-formulation, or registration requirements. Extended analytical summaries or compatibility documentation can be supplied for key accounts with project-driven evaluation needs.
Business cooperation modes are designed to fit distinct procurement patterns, such as annual tender commitments, rolling forecast-based purchasing, or spot-market sales. For long-term partners, volume reservations and preferential lead times are standard, with escalator clauses on price and supply for market-responsive adjustments. Framework-supply agreements allow for upward or downward revisions in batch size to accommodate demand swings, while urgent supply gaps can be managed with split shipments or expedited release documentation where technically supportable.
Clients demanding rapid registration support for new filings benefit from integrated regulatory and technical file assistance, including direct communication with our regulatory affairs and technical teams for document alignment, deficiency response, and dossier customization. Our technical liaisons can join procurement and R&D calls as required, ensuring all specific manufacturing and downstream processing needs are understood and reflected in each procurement cycle.
Ofloxacin tablet manufacturing currently draws research attention to polymicrobial infection management, pediatric dosage development, and resistance pattern analysis. Production teams focus on adjusting crystal forms and particle size distributions, which significantly influence disintegration time and downstream bioavailability. R&D departments often trial new excipient combinations and film-coating methods to address stability during storage in varying climates.
Manufacturers see strong interest in fixed-dose combinations, especially for respiratory, urinary, and gastrointestinal indications. Formulation teams monitor direct compression strategies to prevent active ingredient segregation, impacting uniformity in combination tablets. Demand for pediatric dispersible grades has pushed R&D toward taste-masked formulations, with flavoring and sweetener systems evaluated for compatibility and stability during scale-up.
The primary technical obstacles lie in impurity profile control—particularly for degradation products forming under heat or moisture during tablet compression. Maintaining batch-to-batch consistency in dissolution profiles remains a quality focus, requiring calibration of granulator and coating parameters. Notably, recent in-house process validation efforts have minimized process-related residual solvents by optimizing drying cycles, with routine audits of solvent recovery and air handling.
Tablet consumption for ofloxacin is projected to remain stable in mature pharmaceutical markets, with moderate growth in emerging Asia-Pacific and Africa due to expanding access to oral anti-infective therapy. Demand for tailored grades, such as film-coated versus uncoated tablets, is expected to increase as prescribers respond to patient-centric requirements and hospital procurement moves to tighter specification-driven purchasing.
Process automation in weighing, blending, and online tablet inspection continues to advance batch reproducibility and operator safety. Production managers evaluate continuous manufacturing lines but retain stepwise batch granulation for critical grades needing specific flow and compression traits. Raw material traceability receives investment, especially for APIs and excipients with supply chain vulnerability, which reduces variance in impurity load and improves both quality assurance and regulatory compliance.
Continuous improvement programs target solvent reduction in API synthesis and tablet film-coating operations. Technical teams have adopted aqueous coating systems where pharmacopoeial tests permit, and assessments for solvent recovery have become mandatory for process routes involving volatile organics. Packaging teams collaborate on primary blister choices that balance barrier protection against recyclability targets specified by downstream pharmaceutical partners.
Clients typically require application-specific support, ranging from fine-tuning tableting parameters on rotary presses to guided selection of auxiliary agents compatible with high-activity grades. In-house technical specialists draw on pilot-scale and production-scale results to answer root cause investigations into failed dissolution runs or unexpected visual defects.
Formulators adapting to local excipient supplies in export destinations often request troubleshooting assistance to mitigate sticking, capping, or uneven coating. Troubleshooting advice depends on whether the observed variability links to environmental conditions (humidity/temperature) or mechanical factors like punch wear and tooling selection. Direct data sharing under controlled confidentiality is routine for customizing tablet compression profiles and optimizing storage recommendations to reflect real-world distribution networks.
Quality control and technical service departments maintain batch sample retention and documentation in accordance with regional regulatory expectations. Customers with repeat orders benefit from ongoing trend analysis—tracking critical quality attributes (assay, degradation product levels, disintegration) against agreed specification windows. Any confirmed out-of-specification event triggers a full traceability exercise, including a joint review of raw material certificates, process logs, and environmental monitoring records. Customized training and audit support can be arranged for partners facing revised regulatory inspection criteria or updating plant workflows.
Our facility oversees the full cycle of Ofloxacin tablet manufacturing, from pharmaceutical-grade powder handling to compression and coating. Production lines operate under standard operating procedures, tracked batch by batch through an in-house digital system. All raw materials come under real-time scrutiny for identity, purity, and compliance with pharmacopoeia standards before any processing stage. Our engineering team maintains every piece of tablet machinery, ensuring consistency in physical properties, dissolution, and assay values.
Ofloxacin tablets serve as active pharmaceutical ingredients primarily for human health. These tablets move through hospital and clinical channels, pharmacy chains, and integrated health service providers. Veterinary operations, municipal health authorities, and government supply frameworks often require direct bulk quantities. Industrial project managers and procurement officers know that regulatory traceability and audit support from the original plant guarantee smooth qualification and minimize approval cycles during large-scale sourcing.
We run a controlled quality control laboratory with validated HPLC protocols, reference standards, and audit records. Each lot undergoes full-spectrum analysis before packing, with retained library samples for at least three years. In-process checks monitor tablet hardness, thickness, mass, content uniformity, friability, and microbial limits. Inspection records stay open to authorized customer quality teams for technical evaluation and plant audits.
We handle a range of packaging formats, including HDPE drums lined with anti-static foil, double-layered fiber canisters, and export-grade cartons designed for warehouse palletization. Our team manages serialized labeling, barcoding, and packaging integrity tests. Dedicated lines for export orders help maintain lead time commitments for multi-container shipments or time-sensitive projects. Standard batch sizes run from medium-scale to container-load, ready for integration into regional or global distribution programs.
Industrial customers routinely submit validation questions, regulatory certifications, and process qualification requirements. Our technical team works directly with formulation scientists and industrial buyers to resolve documentation, stability studies, and impurity profile clarifications. Plant managers and QA specialists are available for site audits, regulatory inspections, and full data traceability requests associated with production, quality, and distribution runs.
Direct supply from our site eliminates delays typical in fragmented distribution models. Transparent scheduling and repeat batch manufacturing ensure volume reliability. Project procurement managers reduce risk with complete documentation and global compliance support. Distributors secure contract supply backed by predictable lead times and professional after-sales technical service. By maintaining integrated process control, on-site analytical verification, and scalable packaging systems, we deliver dependable solutions to manufacturers, distributors, and institutional buyers seeking a direct partnership with an experienced Ofloxacin tablet producer.
As the direct manufacturer responsible for the entire production chain of Ofloxacin tablets, we have an in-depth understanding of the product’s pharmacokinetics and why it matters to formulators, healthcare professionals, and downstream partners. This perspective comes from hands-on experience in both formulation and process validation, rather than secondhand information.
Ofloxacin, a fluoroquinolone antibiotic, relies on consistent absorption and dependable bioavailability to deliver its intended therapeutic effect. We prioritize controlling key variables—particle size, crystal form, excipient blend, and tablet hardness—to produce predictable results lot after lot. Oral Ofloxacin typically reaches peak plasma concentrations roughly 1 to 2 hours after administration. This rapid absorption can be attributed to its moderate water solubility and careful formulation. Consistency here means practitioners can anticipate therapeutic blood levels in a timely manner, which is critical for acute infection control.
In our manufacturing process, factors such as hydrophilic excipient choice, granule sizing, and compression force directly affect how quickly the drug becomes available after ingestion. We avoid excessive binders and disintegrants that could slow dissolution. Our products return a high level of batch-to-batch reproducibility due to automated controls and in-process testing. We regularly carry out dissolution testing in compliance with global pharmacopeias. The aim is rapid and complete release in simulated gastric fluids, supporting the observed fast onset in vivo.
Bioavailability with Ofloxacin formulations typically exceeds 95 percent. That means nearly all of the active drug reaches systemic circulation, making oral administration comparable to intravenous options for most indications. This feature arises from Ofloxacin’s chemical stability across a broad pH range and its minimization of first-pass hepatic metabolism. By carefully refining our granulation and coating techniques, we restrict pharmacokinetic variability, so prescribers get predictable exposure per standard dose. Recurring investment in precision coating machinery and stringent assay checks at every major manufacturing step support this reliability from a manufacturer’s perspective.
We have seen how small deviations in moisture content or excipient purity can produce noticeable ripples in both dissolution rate and bioavailability. Our standard process includes controlled environments and rigorous raw material vetting. Technical teams perform regular in-house audits and stability studies, reinforcing the product’s dependable performance across shelf life. Stability data have shown that our Ofloxacin tablets retain both high assay and rapid disintegration even at extended storage temperatures.
Issues sometimes arise due to patient-specific variables, like food interactions, antacids, or gastric pH changes. From our side, we minimize such impacts by opting for excipients that do not interact with common nutritional supplements and by selecting film coatings that endure mild acidity. Our responsibility does not end at the tablet press—for customers requiring modified dosage forms or pediatric-specific strengths, our formulation scientists are able to offer technical insights and batch customization.
Our commitment to manufacturing integrity and process control enables us to support clinical outcomes and drive trust in every Ofloxacin tablet we supply. We back up this commentary with real-world data from our quality assurance labs and welcome technical queries for deeper information. Pharmacokinetic reliability is not a theoretical ideal in our factory—it’s built step by step into every batch we ship worldwide.
A steady flow of large-scale medicine orders like Ofloxacin Tablets keeps production lines running at maximum efficiency and allows us to offer the best value. From our factory floor, minimum order quantities serve both operational and quality priorities. Our MOQ for Ofloxacin Tablets has developed over years of practical experience balancing efficient batch production with market demand. Typical requirements start at 100,000 tablets per dose strength, which suits the realities of high-speed tablet compression, packaging, and consistent batch validation. This approach safeguards not only the product quality but also gives buyers cost advantages through economies of scale. We maintain this MOQ to avoid underutilized equipment and to achieve the uniformity that regulatory markets expect.
Depending on the regional regulatory environment, buyers may ask for different packaging types. We produce standard bottle counts, hospital bulk packs, or customized counts as agreed in contract terms. Adjusting packaging formats can marginally affect the lead time, but core MOQ remains consistent. Our in-house blistering and bottling equipment is set up to handle both high-volume and multi-format runs, so flexibility to market nuances never comes at the expense of our scheduled output.
Lead time planning is central for any bulk tablet procurement. As a direct manufacturer, we keep production closely aligned with raw material availability, validation cycles, and, most importantly, packaging processes. Based on current GMP conditions and procurement cycles for key inputs, standard lead time ranges between four to eight weeks for repeat orders. For new orders requiring product registration, artwork approval, or new analytical documentation, the lead time can extend beyond ten weeks. These timeframes factor in laboratory release, stability monitoring, and final QA clearance.
Unexpected order surges sometimes place pressure on schedules, but our supply chain team regularly secures additional capacity through shift adjustments or prioritized campaigns. Critical hospital supply lines have seen us fast-track certain orders down to three weeks from contract signing to dispatch, but such arrangements rely on pre-approved packaging, available raw material, and validated specifications in place.
Minimum order volumes protect all parties. On the manufacturing side, any batch below 100,000 units would command an outsized share of changeover labor, line downtime, and analytical effort compared to finished yield. Higher MOQs ensure uninterrupted operation of blending, tableting, and coating equipment and provide stable employment for factory teams. Regular batch runs also help us maintain inventory for sudden needs in the healthcare sector.
Lead times reflect more than raw production—they represent the time needed to achieve validated, compliant, and ready-to-ship pharmaceuticals. As a finished formulation producer, we do not warehouse generic or “stocked” finished tablets for open sale. Each contract batch of Ofloxacin Tablets requires a unique process—GMP recordkeeping, packaging specific to each customer, and national documentation. Realistic lead times help procurement teams prevent out-of-stock risks and avoid supply chain stress.
Large-volume tablet production is a partnership from the start. We encourage buyers to share order forecasts and discuss annual demand patterns, which helps us plan both production and inbound materials effectively. This proactive approach lets us keep commitments for large government tenders, group purchasing agreements, and long-term pharmaceutical supply contracts. For organizations making recurrent purchases, we can schedule staggered deliveries anchored to set lead times, stabilizing both our output calendar and the buyer’s stock management.
Reliable global supply of Ofloxacin Tablets only works when every batch reaches its destination intact and with guaranteed quality. Our production lines turn out finished tablets under strict GMP conditions, but the job doesn’t stop at the last pill pressed. We invest years in perfecting logistics and compliance for each export shipment, staying vigilant on every changing international regulation. Clean, consistent storage and shipping protect both the medicine and our partners’ reputations. Regulatory requirements keep moving, so only hard-earned, hands-on experience shows what matters most.
Ofloxacin Tablets leave our controlled environments with one aim: keep them as stable as they are the moment we run batch assays. Ambient temperature remains the gold standard for ofloxacin formulations. Our own data, matched by published studies, backs room temperature storage: 15 – 25°C delivers reliable tablet stability throughout shelf life. Shipping runs risk when tablets experience frequent temperature shifts or high humidity, especially in uninsulated containers or in hot climates. Moisture damages protective films and affects the crystalline structure, so we only use packaging with proven moisture barriers. Desiccants, triple-laminated alu-alu packs, and validated HDPE bottles form our basic protection line. These approaches outlast the average transit delays or rough cargo handling. Any customer looking for even longer shelf life can request customized packaging upgrades.
Every batch ships with a batch-specific Certificate of Analysis, validated by our on-site QC and signed off by our Qualified Person. For international shipments, documentation goes beyond a standard COA. We provide legalized certificates if requested, along with full copies of product registration, pharmacopoeial compliance (we produce to both USP and EP monographs), and shipping-specific stability data. Countries require varied formats for import permits and customs clearance; our documentation team stays updated year-round, so paperwork never lags behind actual product readiness.
Pharmaceuticals moving through global supply chains face constant inspection. Stringent rules from the US FDA, the European EMA, and customs in the Middle East or Asia all expect watertight labeling, traceable serial numbers, and real-time temperature monitoring for select routes. Our shipping team equips each major consignment with calibrated temperature indicators. If our partners request continuous monitoring, we provide bluetooth-enabled dataloggers sealed in the master cartons. These records are archived for every shipment. Any deviation above 25°C triggers an automatic review by our technical managers, with corrective actions launched before product lands in the client’s warehouse.
Our standard packaging has evolved through direct feedback from overseas customers and long-haul shipping trials. Strong outer cartons withstand compression and humidity; security-sealed inner packs deter tampering. Each secondary pack displays all regulatory-accepted batch details—expiry, manufacturing, batch number, and country-specific symbols or barcodes—clearly printed in the recipient’s language if required. For sea freight consignments, we recommend insulation liners in containers for hot climates. Air freight usually allows better control, but even then we avoid pallet stacking that could crush inner packs. Our technical team remains on call throughout shipping periods to support our clients if rare transit issues arise.
Global pharmaceutical transport standards only grow stricter with each year. We commit both resources and direct technical oversight to stay ahead—never entrusting our product quality to blind luck or guesswork. Storage and shipping protocols result from continuous review, based on stability data generated in our own labs and true-to-life transit testing. Our regulatory team monitors all destination country rules for controlled medicines or antimicrobial products. We work with our customers to resolve import challenges or auditing queries, always from a manufacturer’s perspective—not a middleman. Our aim remains the same as on day one: give every partner total confidence in the product received and the process behind it.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
